BioWorld

Oct. 18, 2010

View Archived Issues

Still Seeking Partner, Anadys Adds $25M for HCV Drug Trial

Having yet to sign a partnership for hepatitis C drug ANA598, Anadys Pharmaceuticals Inc. is pulling in $25 million in a public offering to support an upcoming Phase IIb study of the non-nucleoside polymerase inhibitor. (BioWorld Today) Read More

NewCo News: FerroKin to Eliminate Iron Overload with 1 Dose/Day

Read More

Worms, Women's Fertility Decline In Similar Ways

Read More

Questcor Gains FDA OK for Infantile Spasms Drug

Read More

Stock Movers

Read More

Corrections & Clarifications

Read More

Other News To Note

Read More

Earnings Roundup

Read More

Clinic Roundup

Read More

Bench Press

Read More